Exclusive Summary

• UB785 is a Phase II, potential Best-in-Class oral dual 5-HT2AR inverse agonist/5-HT2CR antagonist targeting a massive unmet medical need in ADP, PDP, and NSS—markets currently lacking safe and highly effective approved treatments.
• It demonstrates extraordinary differentiation over the current Standard of Care, Pimavanserin, and the pipeline competitor ACP-204, boasting a 16-fold higher in vitro potency and vastly superior blood-brain barrier penetration (2 to 10-fold higher CSF/brain exposure).
• UB785 decisively overcomes the infamous QTc prolongation and cardiotoxicity liabilities that caused FDA rejections for competitors, proven by a 10-fold safer hERG IC50 margin and clean cardiac safety data in completed Phase I human trials.
• Administered as a highly compliant QD (once-daily) oral capsule and protected by a robust global patent portfolio (PCT filed in 2023, entering the US, EU, Japan, etc.), UB785 presents a highly de-risked and lucrative license-out asset for global pharma companies targeting blockbuster CNS indications.

Asset Materials

Contact Us for Full Materials